ALK-Abelló A/S has introduced EURneffy®, the pioneering adrenaline nasal spray, to the German market, offering a needle-free option for managing severe allergic reactions in both adults and children. This innovation marks a significant advancement in emergency allergy treatment, enhancing accessibility and ease of use.
Innovative Design Enhances Emergency Response
EURneffy® stands out with its user-friendly, needle-free administration, making it simpler for individuals to administer adrenaline during critical moments. The spray’s extended shelf life of 30 months and superior temperature stability surpass existing adrenaline auto-injectors, ensuring reliability when emergencies arise. ALK’s Senior Vice President of Commercial Operations in Europe, Flora Beiche-Scholz, emphasized the product’s potential to improve emergency response and increase the likelihood of successful outcomes for allergy sufferers.
Regulatory Approval and Future Developments
The European Medicines Agency approved EURneffy® following a comprehensive review of data from over 700 participants, with no serious adverse events reported. The company is also progressing towards the EU regulatory approval of a 1 mg dosage for younger patients, expected by 2026. This expansion aims to address the needs of a broader patient population, further solidifying EURneffy®’s role in allergy management.
– EURneffy® offers a convenient, needle-free alternative to traditional auto-injectors.
– Extended shelf life ensures the medication remains effective for longer periods.
– Ongoing regulatory efforts will expand its use to younger patients.
ALK’s strategic partnership with ARS Pharmaceuticals, Inc. secures exclusive global rights to commercialize neffy®, including EURneffy® in the EU, expanding its reach beyond Germany. This collaboration, which excludes key markets like the USA and Japan until 2026, positions ALK to leverage neffy®’s potential across various regions, enhancing their portfolio in allergy treatments.
The introduction of EURneffy® does not alter ALK’s financial projections for 2025, indicating confidence in the product’s market performance. As an established player in the specialty pharmaceutical sector, ALK continues to focus on innovative solutions for allergy and allergic asthma, supported by robust clinical data and strategic market initiatives.
ALK-Abelló’s commitment to improving allergy treatments is evident in their comprehensive approach, which includes digital innovation, clinical data sharing, and collaboration with healthcare professionals. By expanding their product offerings and enhancing existing treatments, ALK aims to meet the diverse needs of allergy sufferers globally.
ALK’s launch of EURneffy® represents a significant step forward in allergy care, providing a more accessible and reliable option for those experiencing life-threatening allergic reactions. The company’s strategic moves and commitment to innovation are poised to make a substantial impact on the management of severe allergies, promising better outcomes and improved quality of life for patients worldwide.
This article has been prepared with the assistance of AI and reviewed by an editor. For more details, please refer to our Terms and Conditions. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author.
